BioSapien

BioSapien is a biotechnology company that has developed MediChip, a 3D-printed, biodegradable drug delivery platform designed for the localized and sustained treatment of cancer. The technology allows clinicians to attach a thin, patch-like implant directly to a tumor site during surgery or minimally invasive procedures. By delivering targeted medication directly to the cancerous tissue, the platform aims to provide the benefits of chemotherapy while minimizing the systemic exposure and debilitating side effects often associated with traditional cancer treatments, such as fatigue, nausea, and hair loss. The system supports the delivery of multiple drug combinations and is engineered to assist in shrinking tumors to make surgery more viable for a wider range of patients.

This technology is intended to improve the quality of life for cancer patients by reducing treatment-related complications and disruption. By enabling a more targeted approach, BioSapien seeks to transform the standard of care for various cancers and other conditions requiring sustained medication release. Founded in 2018, the company has worked to advance this platform through research, patent development, and regulatory pathways, including engagement with the FDA. BioSapien operates with a mission to improve patient well-being and reduce healthcare costs through its innovations, leveraging a team with experience spanning medicine, engineering, and academia.